AGEX THERAPEUTICS INC (AGE) Stock Price & Overview

NYSEARCA:AGE • US00848H2076

Current stock price

11.1 USD
-1.5 (-11.9%)
Last:

The current stock price of AGE is 11.1 USD. Today AGE is down by -11.9%. In the past month the price decreased by -19.01%. In the past year, price decreased by -52.4%.

AGE Key Statistics

52-Week Range10.9027 - 35.17
Current AGE stock price positioned within its 52-week range.
1-Month Range11.1 - 22.8253
Current AGE stock price positioned within its 1-month range.
Market Cap
421.245M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.37
Dividend Yield
N/A

AGE Stock Performance

Today
-11.9%
1 Week
-23.61%
1 Month
-19.01%
3 Months
-18.02%
Longer-term
6 Months -53.59%
1 Year -52.40%
2 Years -63.04%
3 Years -80.52%
5 Years -92.21%
10 Years N/A

AGE Stock Chart

AGEX THERAPEUTICS INC / AGE Daily stock chart

AGE Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to AGE. When comparing the yearly performance of all stocks, AGE is a bad performer in the overall market: 91.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AGE Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AGE. Both the profitability and financial health of AGE have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AGE Earnings

Next Earnings DateMay 13, 2024
Last Earnings DateMar 29, 2024
PeriodQ3 / 2023
EPS Reported-$0.14
Revenue Reported
EPS Surprise %
Revenue Surprise %

AGE Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

AGE Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

AGE Financial Highlights

Over the last trailing twelve months AGE reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -42.31% compared to the year before.


Income Statements
Revenue(TTM)100.00K
Net Income(TTM)-14.05M
Industry RankSector Rank
PM (TTM) N/A
ROA -115.07%
ROE -166.86%
Debt/Equity 0.08
Chartmill High Growth Momentum
EPS Q2Q%-133.33%
Sales Q2Q%600%
EPS 1Y (TTM)-42.31%
Revenue 1Y (TTM)66.67%

AGE Ownership

Ownership
Inst Owners0%
Shares37.95M
Float21.34M
Ins Owners43.6%
Short Float %N/A
Short RatioN/A

About AGE

Company Profile

AGE logo image AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The firm's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.

Company Info

IPO: 2018-11-29

AGEX THERAPEUTICS INC

1101 Marina Village Parkway, Suite 201

Alameda CALIFORNIA 94501 US

CEO: Michael D. West

Employees: 5

AGE Company Website

Phone: 15106718370

AGEX THERAPEUTICS INC / AGE FAQ

Can you describe the business of AGEX THERAPEUTICS INC?

AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The firm's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.


Can you provide the latest stock price for AGEX THERAPEUTICS INC?

The current stock price of AGE is 11.1 USD. The price decreased by -11.9% in the last trading session.


What is the dividend status of AGEX THERAPEUTICS INC?

AGE does not pay a dividend.


What is the ChartMill rating of AGEX THERAPEUTICS INC stock?

AGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


How is the valuation of AGEX THERAPEUTICS INC (AGE) based on its PE ratio?

AGEX THERAPEUTICS INC (AGE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).


Should I buy AGE stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AGE.


Can you provide the upcoming earnings date for AGEX THERAPEUTICS INC?

AGEX THERAPEUTICS INC (AGE) will report earnings on 2024-05-13, after the market close.